Gene therapy cures 10 patients with rare immune disease: study
Ten infants have been cured of a rare genetic disease called Artemis-deficient severe combined immunodeficiency (ART-SCID), according to research by scientists in the US and Canada.
The study was published by M.J. Cowan et al. in The New England Journal of Medicine.
ART-SCID affects approximately one in 65,000 newborns and causes life-threatening problems with the immune system. It’s caused by faulty copies of a gene that codes for a DNA repair enzyme called Artemis, which is required for the production of functioning immune cells.
The infants were conditioned with an intravenous low-dose of the cancer drug Busulfan before the team injected them with gene-corrected cells. These were obtained through bone marrow harvest and transduced with a lentiviral vector.
No unexpected adverse events were reported in safety assessments up to 42 days after transfusion.
Busulfan toxicity manifested as transient cytopenias: Anemia, Thrombocytopenia and Neutropenia. Four patients developed Autoimmune Hemolytic Anemia between 4 and 11 months after the transfusion, but this was resolved with reconstitution of T-cell immunity.
On follow-up, all the infants had genetically corrected and functional immune cells.
Healthscope issues statement on three hospital patient deaths
Healthscope has issued a statement outlining its response to the deaths of three of its...
IVF incident: "All of us at Monash IVF are devastated"
Monash IVF has confirmed that the embryo of one patient at its Brisbane clinic was incorrectly...
NSW sees ramping reductions across some of its busiest EDs
Some of NSW's busiest emergency departments have seen significant reductions in hospital...
